NCT02044380 - Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Afatinib

40, 30, or 20mg tablets taken once daily, dosage depending on tolerability

Trial Locations (5)

Boehringer Ingelheim Investigational Site, Barrie

Boehringer Ingelheim Investigational Site, London

Boehringer Ingelheim Investigational Site, Newmarket

Boehringer Ingelheim Investigational Site, Toronto

Boehringer Ingelheim Investigational Site, Montreal